Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Zehui Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7590-1239; OpenAlex author ID A5065431596. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2023: 2 papers · 2024: 2 papers · 2025: 6 papers · 2026: 3 papers

Papers 13

  1. Irreversible electroporation is superior to resection for locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1016/j.hbpd.2026.05.003↗
  2. A STING signaling relay from tumor cells to macrophages mediates the improved efficacy of combination chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s12929-026-01226-1↗
  3. Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression. Co-author DOI 10.3389/fimmu.2026.1793161↗
  4. Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC. Co-author DOI 10.1016/j.tranon.2024.102206↗
  5. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis. Co-author DOI 10.1186/s12885-025-13824-7↗
  6. Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.2147/jir.s519779↗
  7. Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation. Co-author DOI 10.3389/fimmu.2025.1546242↗
  8. Efficacy of irreversible electroporation combined with immunotherapy versus irreversible electroporation alone in locally advanced pancreatic cancer: a propens… Co-author DOI 10.3389/fimmu.2025.1620988↗
  9. Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreati… Co-author DOI 10.3389/fimmu.2025.1688440↗
  10. Blockades Adenosine Receptor 2B Suppresses Pancreatic Adenocarcinoma Progression by Inhibiting Leukemia Inhibitory Factor Secretion from Macrophages Co-author DOI 10.21203/rs.3.rs-4829619/v1↗
  11. Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analy… Co-author DOI 10.3389/fmed.2024.1486750↗
  12. Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery. Co-author DOI 10.1007/s00432-023-04703-4↗
  13. Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.2147/jir.s404900↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pu Xi · 10 shared papers, 2023–2026 · strength 2.64
  2. Dailei Qin · 9 shared papers, 2023–2025 · strength 2.23
  3. Lingmin Jiang · 7 shared papers, 2024–2026 · strength 1.86
  4. Shengping Li · 5 shared papers, 2023–2026 · strength 1.21
  5. Shengping Li · 4 shared papers, 2024–2026 · strength 1.07
  6. Ran Wei · 4 shared papers, 2023–2025 · strength 0.96
  7. Chaobin He · 3 shared papers, 2025–2026 · strength 0.85
  8. Shengping Li · 2 shared papers, 2025 · strength 0.57
  9. Yize Mao · 2 shared papers, 2023–2026 · strength 0.44
  10. Honglu Ding · 2 shared papers, 2023 · strength 0.39
  11. Chao-Bin He · 1 shared paper, 2026 · strength 0.30
  12. Ran Wei · 1 shared paper, 2025 · strength 0.28
  13. Honglu Ding · 1 shared paper, 2026 · strength 0.25
  14. Xiaojun Xia · 1 shared paper, 2026 · strength 0.25
  15. Qiuxia Yang · 1 shared paper, 2026 · strength 0.25
  16. Jing Xue · 1 shared paper, 2026 · strength 0.25
  17. Qiuxia Yang · 1 shared paper, 2023 · strength 0.19
  18. Ruiqi L. Wang · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.